Lonely At The Top? Not In OTC Sector As Bayer, GSK/Novartis Challenge J&J
This article was originally published in The Tan Sheet
Bayer closes its acquisition of Merck & Co.’s consumer business, aiming to become the top OTC player and saying other consumer product acquisitions could follow. Glaxo and Novartis look to close their agreement to combine their OTC businesses in the first half of 2015.
You may also be interested in...
J&J is “very excited about the possibility of consumer becoming a bigger part of our business,” CFO Caruso says, noting it hopes to grow the business organically and through acquisitions. But J&J first must complete its obligations under a consent decree related to manufacturing quality problems.
FDA will wield tight oversight of Johnson & Johnson subsidiary McNeil Consumer Healthcare's OTC manufacturing operations under a consent decree filed after the firm's quality-control changes failed to satisfy the agency.
Industry trade groups say FDA decision against starting rulemaking for lawful use of hemp ingredients is not only overdue but failed to clear the air for businesses making or using the ingredients.